A biopharmaceutical company focused on discovering, developing, and commercializing innovative medicinal therapies. The company specializes in immunotherapy treatments, with its lead candidate ivonescimab, a bispecific antibody combining PD-1 blockade with anti-angiogenesis for treating non-small cell lung cancer and colorectal cancer.